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Abstract 
Background: Thyroid hormones are fundamental in regulating normal body functions like 
metabolism, development, and reproduction. There are a limited number of studies examining 
the association between thyroid dysfunctions and heavy metals, particularly population-based 
studies. The current study aimed to examine this relationship in the U.S. population. 
Method: The current study used data of the National Health and Nutrition Examination Survey 
from 2007 to 2012. Study population included adults older than 20 years old without any 
medication that might impact thyroid hormones. Based on the clinical standard of thyroid 
dysfunctions, eligible participants were classified into two groups by their thyroid hormones: 
abnormal (either subclinical or overt thyroid disease) and normal. Both blood and urinary heavy 
metals were categorized into quintiles. Multivariate logistic regressions were performed to 
explore the effect of heavy metals in thyroid dysfunctions. 
Results: Among 4207 study participants, 302 (7.2%) of them had abnormal thyroid function, 
including 274 (90.7%) subclinical diseases (164 hypothyroidism and 110 hyperthyroidism) and 
28 (9.3%) overt diseases (22 hypothyroidism and 6 hyperthyroidism). Moreover, the current 
study found that urinary cadmium (OR: 2.05, 95% CI: 1.03, 4.06), antimony (OR: 2.24, 95% CI: 
1.27, 3.94), and tungsten (OR: 2.38, 95% CI: 1.02, 5.54) were significantly associated with 
increased odds of thyroid dysfunctions.  
Conclusion: Environmental exposure to heavy metals may pose particular risk to thyroid 
problems. The limited number of overt diseases prevented us from analyzing the effect of heavy 
metal exposure in relation to different thyroid disease status. Future studies should be warranted 
to fully understand the association between heavy metal and specific thyroid dysfunction. 
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Introduction 
Thyroid hormones, including thyroid stimulating hormone (TSH), triiodothyronine (T3), and 
thyroxine (T4), are important biomarkers of thyroid functions. Excess or deficiency of hormones 
may result in thyroid disorders like hypothyroidism and hyperthyroidism, the leading common 
endocrine disorders in the U.S. (Vanderpump, 2011). However, thyroid diseases often remain 
undiagnosed. According to The Colorado Thyroid Disease Prevalence Study, among 27 million 
people with thyroid dysfunction in the U.S., approximately haft of them (13 millions) were 
undiagnosed (Canaris et al., 2000). Moreover, Hollowell et al. (2002) estimated the prevalence of 
thyroid dysfunctions based on the National Health and Nutrition Examination Survey 
(NHANES) data. Their study showed that among individuals aged over 12 from 1988 to 1994, 
the prevalence of hypothyroidism was 4.6%, including 4.3% subclinical (asymptomatic) and 
0.3% overt hypothyroidism. Similarly, the prevalence of hyperthyroidism was 1.2%, including 
0.7% subclinical and 0.5% overt hyperthyroidism.  
 
Common risk factors of hyper/hypothyroidism include sex, age, family history, radiation, and 
autoimmune disease like type 1 diabetes (Canaris et al., 2000). In addition, some studies have 
suggested associations between thyroid hormone alteration and exposure to heavy metals. 
Urinary mercury was consistently reported to be inversely associated with T3 and T4, and 
cadmium was positively associated with T3 and T4 (Chen, 2013; Yorita, 2013). In comparison, 
the association between blood and urine lead levels to thyroid hormones remains controversial. 
The study of Chen et al. (2013), used data from NHANES 2007 to 2008, reported that there was 
no association between thyroid hormones and blood lead levels. However, Yorita (2013), using 
the same NHANES population, suggested that lead in both blood and urine was associated with 
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decreased total thyroxine (TT4) at individual level. Additionally, the effect of metals may differ 
by sex. Luo and Hendryx (2014), using NHANES population from 2007 to 2010, observed a 
negative association of lead with TT4, and a positive association of cadmium with total 
triiodothyronine (TT3) among males. Among females, they reported a positive association 
between lead and free thyroxine (FT4) and no association between cadmium and any hormones.  
 
The existing literature has provided suggestive evidence of a relationship between exposure to 
heavy metals and thyroid diseases. Using self-reported thyroid diseases status (any thyroid 
dysfunction), the study of Mendy et al. (2012) found a positive relationship between thyroid 
problems and exposure to urinary cadmium, cobalt, lead, and tungsten, though not statistically 
significant. However, there is a limited number of studies examining this direct association. As 
mentioned, many individuals with thyroid diseases are undiagnosed. The self-reported disease 
status may not accurately measure subclinical hyper/hypothyroidism. Using the combined 
NHANES data from 2007 to 2012, the current study used thyroid hormones to clinically define 




The National Center for Health Statistics Research Ethics Review Board approved the study 
protocol of 2007-2010 (protocol 2005-06), and 2011-2012 (protocol 2011-17) NHANES, and all 
participants provided written informed consent (CDC, 2012). This cross-sectional study used 
NHANES data from 2007 – 2012. A total of 30,442 participants were included initially. The 
continuous NHANES data were designed to be nationally representative for the civilian, non-
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institutionalized population of the United States, with a complex, multistage, probability-
sampling design (CDC, 2012). Thyroid hormones were assessed in all eligible participants aged 
12 years and older from 2007 to 2008, while only assessed in one third randomly selected 
subsample of participants aged 6 years and older from 2009 to 2012. In addition, urinary heavy 
metals were measured in a one third subsample of participants aged 6 years and older from 2007 
to 2012. For the purpose of this study, the study was restricted to the NHANES population with 
available measurements of both thyroid hormones and heavy metals from 2007 to 2012. 
Moreover, the medical condition information was only available for those who aged 20 years and 
older. Thus, the current analyses included data from participants aged ≥20 years old (N=5,279). 
Individuals were further excluded if they met any of the exclusion criteria: were pregnant at the 
time of examination (N=59); had any cancer except non-melanoma skin cancer (N=409); self-
report of taking medications that might have an impact on thyroid hormones, including 
desiccated thyroid, thyroid hormones, Levothyroxine, Liothyronine, and Thyroglobulin (N=278). 
There were 4533 individuals available for thyroid disease categorization (Figure 1).  
 
Primary thyroid hormones of interest included TSH, FT4, and FT3. Eligible participants were 
first classified into three groups: subclinical disease (hyper/hypothyroidism), overt disease 
(hyper/hypothyroidism), and normal status. According to the American Association of Clinical 
Endocrinologists (Garber et al., 2012), the normal TSH range is 0.45 to 4.12 mIU/L for those 
who are not pregnant. Accordingly, subclinical hypothyroidism is defined as individuals with 
elevated TSH (4.12 < TSH < 20 mIU/L) as well as normal FT4 (0.6 ≤ FT4 ≤ 1.6 ng/dL) and FT3 
(2.5 ≤ FT3 ≤  3.9 ng/dL; CDC NHANES Laboratory Procedure Manual, 2012). Subclinical 
hyperthyroidism was defined as individuals with low TSH (TSH < 0.45 mIU/L) and normal FT4 
 5  
and FT3 (CDC, 2012). Overt hypothyroidism were those with high TSH  (TSH > 4.12 mIU/L) 
and low FT4 (FT4 < 0.6 ng/dL) and FT3 (FT3 < 2.5 ng/dL); overt hyperthyroidism were those 
with low TSH (TSH < 0.45 mIU/L) and high FT4 and FT3 (FT4>1.6 ng/dL or FT3 > 3.9 ng/dL). 
Normal group was defined as those with all TSH, FT3 and FT4 within normal limits. Participants 
with either subclinical or overt thyroid diseases were subsequently defined as abnormal status. In 
addition, 326 individuals were excluded from the analyses because they did not meet any of the 
disease definitions and might have other thyroid diseases that were of interest to the study. After 
exclusions, 4207 individuals were available for data analyses (Figure 1).  
 
Both urinary and blood metals were included in the analyses only if they were available for all 
three years. This excluded urinary tin, manganese, strontium and blood manganese and selenium, 
which were available for years 2011 to 2012 only. Two urinary metals were further excluded 
from the analyses because more than 90% of the sample was below the limit of detection (LOD) 
(urinary platinum: 92.0% below LOD; urinary beryllium 99.9% below LOD). Cadmium, lead, 
and total mercury were measured in both blood and urine.  
 
We used multivariate logistic regression to estimate odds ratios (ORs) and 95% confidence 
intervals (95% CIs). Each heavy metal was first examined in the regression model individually 
and all urinary/blood metals were examined together, while adjusting for other covariates. Both 
blood and urinary metals were categorized into quintiles. For metals that were detectable in less 
than 95% of the sample (urinary cadmium, antimony, tungsten, uranium, manganese, tin, blood 
mercury and cadmium), percentage below LOD was used as the reference group, and percentage 
above LOD was divided into quartiles. Metals that were detectable in more than 95% of the 
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sample were divided into quintiles directly, with the first quintile as the reference group. 
Multicollinearity was assessed among urinary metals and among blood metals respectively. 
Covariates included in the analyses were age (continuous), body mass index (BMI; underweight: 
less than 18.5 kg/m2; normal: 18.5 to 24.9 kg/m2; overweight: 25-29.9 kg/m2, and obese: more 
than 30 kg/m2), race (non-Hispanic white, non-Hispanic black, and other), sex (female and 
male), total lipid (continuous), and urinary creatinine (continuous). Total lipid was calculated as 
suggested by CDC, total lipid = 2.27 * total cholesterol + triglycerides + 62.3 (CDC, 2012). 
Creatinine was used as a covariate to count for variations in participants’ age, gender, and 




Among 4207 study participants, 302 (7.2%) had abnormal thyroid function. Specifically, 274 
(90.7%) of those with abnormal function had subclinical thyroid diseases (164 hypothyroidism 
and 110 hyperthyroidism), and 28 (9.3%) had overt thyroid diseases (22 hypothyroidism and 6 
hyperthyroidism). The remaining 3905 individuals were free of any thyroid disease. Moreover, 
among 174 participants reported having thyroid disease history, 68 of them were still diseased 
(but were not taking any medications that affected thyroid hormones). The average age of the 
disease-free participants was 47.6 years old (Table 1). In comparison, the average age of the 
abnormal group (both subclinical and overt) (p=0.002) and subclinical group (p=0.005) was 
significantly older than the normal group (50.8 years old and 50.6 years old, respectively). The 
majority of the study participants were Non-Hispanic Whites and obese, which were comparable 
among the study groups. All metals were detected in at least 70% of study participants. Urinary 
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cesium was detected in all study participants. Total blood mercury was detected among 91.8% 
participants free of any disease, which was significantly different from that of abnormal and 
subclinical participants. About 92.8% abnormal individuals (p=0.007) and 87.2% subclinical 
individuals (p=0.007) were detected with blood mercury. 
 
No multicollinearity was found in either urinary or blood metals (Table 4 a & 4b). Odds ratios of 
individual urinary metals associated with thyroid disease are shown in Table 2, controlling for 
total lipids, sex, BMI, age, race, and urinary creatinine. As compared to the normal reference 
quintile group, the higher quintiles of urinary antimony and tungsten were significantly 
associated with increased odds of thyroid diseases. The odds of any thyroid disease (either overt 
or subclinical diseases) of those at the third quintile of antimony exposure was 2.24 times the 
odds of the reference quintile (95% CI: 1.27, 3.94). Similarly, the odds of thyroid disease of 
those at the forth quintile of antimony was 2.83 times higher than those at the reference group 
(95% CI: 1.57, 5.11). Urinary cadmium was barely significant in relation to thyroid disease when 
examined individually. After controlling for other metals in urine, the odds of disease for the first 
quintile of urinary cadmium was significantly higher than the odds of reference group (OR: 2.05, 
95% CI: 1.03, 4.06), and urinary tungsten was significantly associated with subclinical thyroid 
diseases (OR: 2.38, 95% CI: 1.02, 5.54) (Table 2). No significant association was observed 
between blood metals and thyroid diseases (Table 3). 
 
Discussion 
Our study found that urinary cadmium, antimony, and tungsten were significantly associated 
with a higher odds of thyroid dysfunctions. Being consistent with our results, Mendy et al. 
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(2012), using NHANES data from 2007 to 2008, reported positive relationships between 
cadmium (OR=1.40, 95% CI: 0.78-2.50) and tungsten (OR=1.58, 95%CI: 0.93, 2.70) and self-
reported thyroid disease, though not significant.  
 
Cadmium is an established environmental toxicant that may disrupt thyroid hormone secretion 
(Vacchi-Suzzi et al., 2016). It interrupts with normal thyroid function through changes in 
peripheral hormone receptors, which eventually disturb the normal conversion of T4 into active 
T3 (Buha et al., 2018). Previous studies have consistently reported positive associations between 
urinary cadmium and individual thyroid hormones including total and free T3 and T4 (Chen et 
al., 2013; Yorita et al., 2013;). In addition, Yorita et al. (2013) found a negative relationship 
between cadmium and TSH, which was a suggestive pattern of hyperthyroidism. In our study, 
only low levels of urinary cadmium (first quintile) was associated thyroid abnormality, and the 
observed association became weakened/insignificant among participants with only subclinical 
disease status, which indicated an association between overt thyroid disease and cadmium 
exposure. Additionally, the discrepancy in results of urinary and blood cadmium was noticed. 
Only urinary cadmium was significantly associated with the outcomes. One possible reason may 
be that the urinary test is mainly used to reflect long-term heavy metal exposure, while the blood 
test reflects both long-term and recent exposures (Vacchi-Suzzi et al., 2016). Since the majority 
of the study participants were assumed to be naturally exposed to heavy metals in the 
environment, a urine test might be a more valid specimen for long-term exposure to heavy 
metals. 
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In addition to cadmium, the study of Yorita et al. (2013) has reported an association of urinary 
tungsten and increased TSH, but not FT3 or FT4. This finding suggested that tungsten was 
correlated with subclinical hypothyroidism, which was consistent with our result that high level 
of tungsten exposure was significantly associated with subclinical thyroid diseases. Underlying 
mechanism directly linking tungsten and thyroid diseases still remained unclear. But based on 
the animal study of Chatterjee et al. (1973), at a high concentration, tungsten reduced the 
ascorbic acid status in the adrenal gland of rats. In addition, studies have found that ascorbic acid 
(vitamin c) played a role in lowering stress hormones like cortisol produced by adrenal gland 
(Peters et al., 2001). Decreased vitamin C level associated high concentration of tungsten would 
lead to potential impairment of normal cortisol secretion, which further lead to elevated TSH 
level and subclinical hypothyroidism (Walter et al. 2012).  
 
The current study also found a significant association between high exposure to antimony in 
relation to thyroid dysfunctions. Although studies evaluating the impact of antimony on thyroid 
functions are limited, there is suggestive evidence supporting this observed relationship. Major 
sources of exposure to antimony include contaminated water, food, and occupational contact 
(Cooper et al., 2009). There was a concern regarding non-occupational exposure to antimony 
from the polyethylene terephthalate (PET) bottles or containers, as several studies from Europe 
and Canada indicating antimony leaching from PET bottled waters under summer time high 
temperature inside of car or garage (Westerhoff et al., 2008). Accordingly, Sax (2010) reported 
antimony that migrated from PET plastic bottled water to be a potential endocrine disruptor. 
Further, an animal study by Poon et al. (1998) showed that histopathological changes were 
presented in liver and thyroid of rats being exposed to the highest dose of antimony 
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contaminated drinking water. They found increased epithelial height and nuclear vehiculation in 
the thyroid as well as cytoplasmic vacuolation and inclusion in the pituitary gland, which might 
have negative impacts on TSH production (Poon et al., 1998). However, using NHANES data 
from 2007 to 2008, Yorita et al. (2013) reported no such association between antimony and any 
of the individual thyroid hormone, suggesting no association between thyroid disease and 
antimony. Differences between the current study and the study of Yorita (2013) could be due to 
the use of combined data from 2007 to 2012 by the current study and different methods of 
analysis. 
 
One limitation of our study was that we used selected thyroid hormones to classify both overt 
and subclinical thyroid diseases. It should be noted that our main interests were primary 
subclinical or overt thyroid diseases, and there are other diseases that may cause changes in 
thyroid hormones. Thus, results should be interpreted with caution. Due to the limited number of 
overt thyroid diseases, we were not able to analyze the effect of heavy metal exposure and 
specific thyroid disease status. Furthermore, the cross-sectional nature of the NHANES data 
prevents us from making casual inferences of the observed associations. Based on the 
inconsistence of the observed association in urinary antimony, more population-based 
observational studies regarding exposure to heavy metal, particularly those understudied ones, in 
relation to thyroid diseases should be warranted.  
Conclusion 
Our study showed that environmental exposure to cadmium, antimony, and tungsten may pose 
particular risk to thyroid diseases. More studies should be warranted to fully understand the 
association between environmental heavy metal and subclinical or overt hyper/hypothyroidism.  
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Table 1. Selected characteristics of study participants by disease status.      
 
Characteristic 
Normal (N= 3905) *    Abnormal (N=302) *    Subclinical (N=274) * 
N %   N % 
p-
value   N % 
p-
value 
Age (mean, Sd) 47.6 17.0  50.8 18.0 0.002  50.6 18.1 0.005 
Total lipids (mean, Sd) 637.2 164.1  637.2 148.8 0.977  637.5 146.8 0.985 
Sex       0.380    0.603  Male 2016 51.6  148 49.0   137 50.0  
 Female 1889 48.4 
 154 51.0   137 50.0 
 
Race/ethnicity       0.396    0.334  Non-Hispanic White 1633 41.8  138 45.7   127 46.4  
 Non-Hispanic Black 822 21.1 
 57 18.9   52 19.0  
 Other 1450 37.1 
 107 35.4   95 34.7  
BMI      0.490    0.441 
 Underweight 64 1.7  6 2.0   6 2.2  
 Normal 1084 28.1 
 91 30.4   87 31.9  
 Overweight 1325 34.4 
 90 30.1   84 30.8  
 Obese 1380 35.8 
 112 37.5   96 35.2  
 Median < LOD**  Median < LOD   Median < LOD  
Urinary metals      
 
   
 
 Arsenic (ug/L) 8.6 1.5 
 7.6 1.4 0.826  7.7 1.5 0.980 
 Cadmium (ug/L) 0.2 6.4  0.2 8.1 0.251  0.2 8.6 0.163 
 Lead (ug/L) 0.5 3.0  0.5 2.4 0.548  0.5 2.2 0.488 
 Mercury (ug/L) 0.4 3.4  0.4 3.0 0.848  0.4 3.1 0.899 
 Barium (ug/L) 1.3 0.8  1.1 1.0 0.669  1.1 1.1 0.552 
 Cobalt (ug/L) 0.3 0.5  0.3 0.3 0.667  0.3 0.4 0.741 
 Cesium (ug/L) 4.5 0.0  4.2 0.0 NA  4.3 0.0 NA 
 Molybdenum (ug/L) 42.9 0.1 
 42.0 0.0 0.694  43.1 0.0 0.708 
 Antimony (ug/L) 0.1 31.8  0.1 27.6 0.134  0.1 28.3 0.225 
 Thallium (ug/L) 0.2 0.6  0.1 0.7 0.777  0.1 0.7 0.676 
 Tungsten (ug/L) 0.1 13.6  0.1 10.8 0.166  0.1 11.5 0.331 
 Uranium (ug/L) 0.0 14.6  0.0 11.5 0.139  0.0 11.5 0.168 
Blood metals         
  
 Cadmium (ug/L) 0.4 17.1 
 0.3 21.5 0.142  0.4 20.3 0.314 
 Lead (ug/dL) 1.3 0.3  1.3 0.6 0.451  1.4 0.6 0.401 
  Total Mercury (ug/L) 0.9 8.2   0.8 7.2 0.007   0.8 12.8 0.007 
* numbers may not add to total due to missing value 
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Table 2.  Adjusted ORs* of individual urinary metals in relation to thyroid diseases. 
  Normal (N=3905)   Abnormal (N=302) **   Subclinical (N=274) ** 
    N   N OR† (95% CI) Adj. OR‡ (95% CI)   N OR† (95% CI) Adj. OR‡ (95% CI) 
cadmium 




53 1.00 1.00 
 
49 1.00 1.00  
Q1 755 
 
75 1.88 (0.99, 3.58) 2.05 (1.03, 4.06) 
 
66 1.88 (0.96, 3.65) 2.07 (0.98, 4.22)  
Q2 768 
 
49 1.23 (0.63, 2.42) 1.32 (0.63, 2.73) 
 
42 1.03 (0.50, 2.11) 1.13 (0.52, 2.47)  
Q3 764 
 
60 1.37 (0.69, 2.74) 1.45 (0.68, 3.10) 
 
56 1.38 (0.68, 2.83) 1.47 (0.67, 2.23)  
Q4 776 
 
60 1.07 (0.50, 2.27) 1.02 (0.44, 2.34) 
 
56 1.11 (0.51, 2.43) 1.05 (0.44, 2.51) 
antimony 




82 1.00 1.00 
 
76 1.00 1.00  
Q1 650 
 
56 1.51 (0.91, 2.52) 1.52 (0.87, 2.63) 
 
52 1.57 (0.92, 2.68) 1.60 (0.44, 2.51)  
Q2 680 
 
47 1.52 (0.88, 2.640 1.57 (0.86, 2.86) 
 
39 1.35 (0.74, 2.45) 1.40 (0.73, 2.69)  
Q3 637 
 
58 2.24 (1.27, 3.94) 2.19 (1.17, 4.08) 
 
52 2.24 (1.24, 4.03) 2.24 (1.16, 4.30)  
Q4 653 
 
54 2.83 (1.57, 5.11) 3.09 (1.60, 5.94) 
 
50 2.77 (1.50, 5.14) 3.11 (1.57, 6.20) 
tungsten 




32 1.00 1.00 
 
31 1.00 1.00  
Q1 839 
 
70 1.76 (0.93, 3.33) 1.81 (0.92, 3.60) 
 
60 1.55 (0.80, 3.03) 1.69 (0.83, 3.48)  
Q2 844 
 
61 1.63 (0.84, 3.17) 1.65 (0.78, 3.46) 
 
56 1.58 (0.80, 3.16) 1.72 (0.79, 3.73)  
Q3 813 
 
67 1.83 (0.92, 3.65) 1.57 (0.72, 3.44) 
 
60 1.76 (0.86, 3.61) 1.62 (0.71, 3.70)  
Q4 815 
 
67 2.55 (1.26, 5.15) 2.13 (0.95, 4.80) 
 
62 2.61 (1.26, 5.41) 2.38 (1.02, 5.54) 
uranium 




34 1.00 1.00 
 
31 1.00 1.00  
Q1 824 
 
77 1.52 (0.83, 2.77) 1.25 (0.66, 2.39) 
 
69 1.44 (0.76, 2.74) 1.26 (0.63, 2.51)  
Q2 836 
 
57 1.10 (0.58, 2.08) 0.88 (0.44, 1.77) 
 
51 1.17 (0.60, 2.28) 0.99 (0.47, 2.08)  
Q3 823 
 
61 1.42 (0.75, 2.69) 1.10 (0.54, 2.25) 
 
58 1.55 (0.79, 3.02) 1.28 (0.60, 2.71)  
Q4 799 
 
68 1.47 (0.77, 2.80) 1.07 (0.52, 2.22) 
 
60 1.46 (0.73, 2.89) 1.11 (0.51, 2.40) 
arsenic 




57 1.00 1.00 
 
52 1.00 1.00  
Q1 744 
 
73 1.07 (0.63, 1.81) 1.01 (0.56, 1.82) 
 
65 1.04 (0.60, 1.81) 1.02 (0.55, 1.90)  
Q2 767 
 
52 0.80 (0.45, 1.45) 0.75 (0.39, 1.44) 
 
46 0.73 (0.39, 1.36) 0.68 (0.34, 1.38)  
Q3 758 
 
62 0.99 (0.57, 1.74) 0.96 (0.50, 1.82) 
 
56 0.97 (0.54, 1.75) 0.96 (0.49, 1.89)  
Q4 792 
 
52 0.88 (0.49, 1.59) 0.83 (0.42, 1.64) 
 
49 0.91 (0.49, 1.69) 0.90 (0.44, 1.83) 
lead 




61 1.00 1.00 
 
57 1.00 1.00  
Q1 773 
 
55 0.85 (0.49, 1.49) 0.73 (0.40, 1.36) 
 
52 0.80 (0.45, 1.42) 0.67 (0.35, 1.27)  
Q2 789 
 
57 1.06 (0.61, 1.85) 0.94 (0.49, 1.78) 
 
46 0.79 (0.44, 1.43) 0.66 (0.33, 1.32)  
Q3 754 
 
61 1.06 (0.58, 1.94) 1.00 (0.49, 2.02) 
 
57 1.02 (0.55, 1.89) 0.90 (0.43, 1.87)  
Q4 762 
 
63 1.07 (0.56, 2.06) 0.89 (0.41, 1.90) 
 
57 0.90 (0.45, 1.77) 0.69 (0.31, 1.53) 
mercury 




67 1.00 1.00 
 
61 1.00 1.00  
Q1 739 
 
56 0.87 (0.49, 1.55) 0.96 (0.52, 1.76) 
 
54 0.89 (0.50, 1.61) 0.96 (0.51, 1.81)  
Q2 760 
 
65 0.94 (0.54, 1.66) 1.01 (0.55, 1.88) 
 
55 0.79 (0.43, 1.46) 0.82 (0.43, 1.60)  
Q3 773 
 
55 0.97 (0.56, 1.70) 1.02 (0.54, 1.91) 
 
50 0.95 (0.54, 1.70) 0.97 (0.50, 1.87)  
Q4 783 
 
56 0.95 (0.55, 1.66) 0.98 (0.52, 1.85) 
 
51 0.89 (0.50, 1.58) 0.86 (0.44, 1.68) 
barium 




52 1.00 1.00 
 
46 1.00 1.00  
Q1 771 
 
74 1.61 (0.95, 2.72) 1.54 (0.88, 2.70) 
 
66 1.41 (0.81, 2.43) 1.33 (0.74, 2.39)  
Q2 760 
 
65 1.63 (0.95, 2.78) 1.59 (0.89 2.87) 
 
61 1.48 (0.85, 2.57) 1.39 (0.75, 2.57)  
Q3 780 
 
55 1.12 (0.62, 2.01) 1.13 (0.58, 2.17) 
 
49 0.98 (0.53, 1.81) 0.96 (0.48, 1.90)  
Q4 769 
 
51 1.12 (0.59, 2.13) 1.07 (0.52, 2.19) 
 
47 1.05 (0.54, 2.03) 0.97 (0.47, 2.04) 
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cobalt 




62 1.00 1.00 
 
55 1.00 1.00  
Q1 773 
 
54 0.80 (0.47, 1.36) 0.64 (0.35, 1.18) 
 
47 0.75 (0.42, 1.33) 0.62 (0.32, 1.20)  
Q2 765 
 
67 1.21 (0.70, 2.08) 1.05 (0.55, 2.01) 
 
62 1.25 (0.71, 2.21) 1.12 (0.56, 2.23)  
Q3 785 
 
48 0.85 (0.45, 1.60) 0.73 (0.34, 1.54) 
 
46 0.90 (0.47, 1.75) 0.78 (0.35, 1.72)  
Q4 747 
 
66 1.16 (0.61, 2.22) 1.05 (0.49, 2.26) 
 
59 1.21 (0.61, 2.38) 1.11 (0.49, 2.48) 
cesium 




70 1.00 1.00 
 
61 1.00 1.00  
Q1 772 
 
55 0.69 (0.40, 1.19) 0.57 (0.30, 1.10) 
 
51 0.73 (0.41, 1.30) 0.71 (0.35, 1.43)  
Q2 750 
 
73 0.82 (0.47, 1.43) 0.66 (0.31, 1.39) 
 
67 0.88 (0.49, 1.58) 0.83 (0.37, 1.86)  
Q3 779 
 
50 0.79 (0.43, 1.45) 0.60 (0.26, 1.39) 
 
44 0.87 (0.46, 1.64) 0.74 (0.30, 1.80)  
Q4 785 
 
49 0.55 (0.27, 1.11) 0.43 (0.17, 1.08) 
 
46 0.59 (0.28, 1.23) 0.49 (0.18, 1.32) 
molybdenum 




59 1.00 1.00 
 
55 1.00 1.00  
Q1 777 
 
53 0.87 (0.50, 1.53) 0.89 (0.48, 1.64) 
 
46 0.88 (0.49, 1.59) 0.93 (0.48, 1.78)  
Q2 762 
 
67 1.60 (0.93, 2.76) 1.52 (0.79, 2.92) 
 
60 1.61 (0.91, 2.85) 1.55 (0.77, 3.11)  
Q3 779 
 
53 1.06 (0.55, 2.02) 0.98 (0.45, 2.12) 
 
47 0.97 (0.49, 1.94) 0.90 (0.39, 2.06)  
Q4 755 
 
65 2.18 (0.60, 4.33) 2.04 (0.92, 4.50) 
 
61 2.28 (0.67, 4.65) 2.03 (0.88, 4.68) 
thallium 




62 1.00 1.00 
 
57 1.00 1.00  
Q1 759 
 
70 0.63 (0.36, 1.11) 0.67 (0.35, 1.28) 
 
60 0.51 (0.28, 1.24) 0.51 (0.25, 1.04)  
Q2 773 
 
67 1.03 (0.61, 1.75) 1.11 (0.56, 2.20) 
 
60 0.99 (0.58, 1.72) 1.03 (0.50, 2.11)  
Q3 782 
 
53 0.72 (0.39, 1.32) 0.79 (0.36, 1.75) 
 
49 0.70 (0.37, 1.31) 0.75 (0.33, 1.72) 
  Q4 771   45 0.73 (0.38, 1.40) 0.88 (0.37, 2.07)   43 0.75 (0.38, 1.46) 0.89 (0.36, 2.20) 
*adjusted for total lipid, sex, bmi, age, race, and urinary creatinine 
    
** numbers may not add to total due to missing value 
    
† univariate analysis  
    
‡ multivariate analysis  
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Table 3. Adjusted ORs* of blood metals in relation to thyroid diseases. 
Normal (N= 3905)   Abnormal (N=302) **   Subclinical (N=274) ** 
  N  N OR† (95% CI) Adj. OR‡ (95% CI)   N OR† (95% CI) Adj. OR‡ (95% CI) 
cadmium          
 
Q0 775  63 1.00 1.00 
 56 1.00 1.00 
Q1 817  49 0.68 (0.40, 1.18) 0.70 (0.40, 1.21) 
 45 0.71 (0.40, 1.27) 0.74 (0.41, 1.31) 
Q2 756  60 1.01 (0.60, 1.69) 1.04 (0.62, 1.75) 
 52 1.03 (0.60, 1.78) 1.09 (0.63, 1.89) 
Q3 779  72 1.00 (0.50, 1.69) 1.02 (0.60, 1.73) 
 65 1.06 (0.62, 1.83) 1.11 (0.64, 1.94) 
Q4 774  57 0.80 (0.47, 1.39) 0.82 (0.46, 1.47) 
 55 0.83 (0.47, 1.48) 0.88 (0.48, 1.60) 
lead   
       
 
Q0 767  55 1.00 1.00 
 51 1.00 1.00 
Q1 814  54 0.82 (0.46, 1.45) 0.82 (0.46, 1.47) 
 45 0.73 (0.40, 1.32) 0.73 (0.40, 1.34) 
Q2 760  67 1.15 (0.67, 2.00) 1.15 (0.66, 2.03) 
 61 1.00 (0.57, 1.78) 1.00 (0.56, 1.80) 
Q3 799  59 0.91 (0.51, 1.63) 0.93 (0.52, 1.69) 
 56 0.85 (0.47, 1.54) 0.86 (0.47, 1.59) 
Q4 761  66 0.87 (0.47, 1.61) 0.86 (0.45, 1.65) 
 60 0.72 (0.38, 1.38) 0.70 (0.36, 1.39) 
mercury   
       
 
Q0 761  70 1.00 1.00 
 66 1.00 1.00 
Q1 757  64 0.91 (0.55, 1.50) 0.91 (0.55, 1.50) 
 54 0.82 (0.49, 1.38) 0.82 (0.48, 1.38) 
Q2 794  47 0.65 (0.37, 1.12) 0.64 (0.37, 1.12) 
 43 0.58 (0.33, 1.04) 0.58 (0.33, 1.04) 
Q3 791  58 0.99 (0.60, 1.62) 1.00 (0.60, 1.65) 
 52 0.94 (0.56, 1.56) 0.95 (0.57, 1.60) 
Q4 798   62 0.90 (0.54, 1.49) 0.90 (0.54, 1.50)   58 0.80 (0.47, 1.36) 0.81 (0.48, 1.38) 
*adjusted for total lipid, sex, bmi, age, and race    
  
** numbers may not add to total due to missing value   
  
† univariate analysis   
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Table 4a.  Correlation coefficients between urinary metals  
Metals 
       (log 
transformed) 
arsenic barium cadmium cobalt cesium molybdenum lead antimony thallium tungsten uranium mercury 
arsenic 1.000 0.032 0.135 0.045 0.148 0.096 0.054 0.082 0.173 0.035 0.041 0.104 
barium - 1.000 0.095 0.117 0.185 0.122 0.075 0.134 0.140 0.035 0.057 0.042 
cadmium - - 1.000 0.131 0.307 0.176 0.168 0.159 0.266 0.039 0.117 0.144 
cobalt - - - 1.000 0.167 0.171 0.056 0.062 0.160 0.039 0.022 0.036 
cesium - - - - 1.000 0.323 0.179 0.135 0.553 0.087 0.111 0.202 
molybdenum - - - - - 1.000 0.119 0.151 0.306 0.129 0.127 0.121 
lead - - - - - - 1.000 0.146 0.157 0.024 0.118 0.041 
antimony - - - - - - - 1.000 0.150 0.059 0.104 0.041 
thallium - - - - - - - - 1.000 0.076 0.088 0.219 
tungsten - - - - - - - - - 1.000 0.042 0.255 
uranium - - - - - - - - - - 1.000 0.029 
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cadmium lead mercury 
cadmium 1.000 0.149 0.027 
lead - 1.000 0.059 
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*any cancer except non-melanoma skin cancer 
*medications that may impact thyroid hormones: desiccated thyroid, thyroid hormones, 
Levothyroxine, Liothyronine, Thyroglobulin 
 
All 2007-2012 NHANES 
participants 
(N=30442) 
Age >= 20 years 
(N=17713) 
Aged < 20 years 
(N=12729) 
Complete thyroid hormone 





Eligible participants for 
disease categorization 
(N= 4533) 
Exclusion applied to 
(N=746): pregnancy 
(N=59), cancer* (N=409), 
medications* (N=278) 
Not meet disease 
definition (N=326) 
Total participants 
(N= 4207) 
